TNF inhibitors in inflamatory bowel disease;Inhibidores del factor de necrosis tumoral alfa en la enfermedad inflamatoria intestinal

Medicina Clinica

Volumn 123, Issue 16, 2004, Pages 627-634

  Casellas I Jordà, Francesc ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Crohns' disease; Infliximab; Treatment of inflammatory bowel disease; Tumor necrosis factor; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; DNA ANTIBODY; ETANERCEPT; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; ONERCEPT; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY PRODUCTION; AUTOIMMUNITY; CROHN DISEASE; DRUG HYPERSENSITIVITY; ENTERITIS; HUMAN; IMMUNOGENICITY; IMMUNOPATHOGENESIS; NONHUMAN; REINFECTION; RELAPSE; REMISSION; REVIEW; SIDE EFFECT; TUBERCULOSIS; ULCERATIVE COLITIS;

EID: 10644226006     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13068441     Document Type: Review

References (95)

1. Casellas F, López Vivancos J. Evaluación de la calidad de vida en las enfermedades digestivas. Gastroenterol Hepatol 2004;27:58-68.
2. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003;361:512-9.
3. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics and ecotherapeutics. Gastroenterology 2001;120:622-35.
4. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
5. Mendoza JL, Murillo LS, Fernández L, Pena AS, Lana R, Urcelay E, et al. Prevalence of mutations of the NOD2/CARD15 gene and relation to phenotype in Spanish patients with Crohn disease. Scand J Gastroenterol 2003;38:1235-40.
6. Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2002;359:331-40.
7. Melgar S, Yeung MM, Bas A, Forsberg G, Suhr O, Oberg A, et al. Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin Exp Immunol 2003;134:127-37.
8. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. En: The Cochrane Library, Issue 4. Oxford: Update Software, 2001.
9. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. En: The Cochrane Library, Issue 4. Oxford: Update Software, 2001.
10. Pearson D, May GR, Fixck G, Sutherland L. Azathioprine for maintaining remission of Crohn's disease. En: The Cochrane Library, Issue 4. Oxford: Update Software, 2001.
11. Alfadhli AAF, McDonald JWD, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. En: The Cochrane Library, Issue 4. Oxford: Update Software, 2004.
12. Sandborn WJ. Evidence-based treatment algorithm for mild to moderate Crohn's disease. Am J Gastroenterol 2003;98(Suppl 12):1-5.
13. Shalaby MR, Aggarwal BB, Rinderknect E, Svedersky LP, Finkle BS, Palladino MA. Activation of human polymorphonuclear neutrofil functions by interferon gamma and tumor necrosis factor. J Immunol 1985;135: 2069-73.
14. Moser R, Schleiffenbaum B, Groscurth P, Fehr J. Interleukin 1 and tumor necrosis factor stimulates human vascular endothelial cells to promote neutrophil passage. J Clin Invest 1989;83:444-55.
15. Van Deventer SJH. Tumor necrosis factor and Crohn's disease. Gut 1997;40:443-8.
16. Borruel N, Casellas F, Antolin M, Llopis M, Carol M, Espin E, et al. Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa. Am J Gastroenterol 2003;98:865-70.
17. Dionne S, Laberge S, Deslandres C, Seidman EG. Modulation of cytokine release from colonic explants by bacterial antigens in inflammatory bowel disease. Clin Exp Immunol 2003;133:108-14.
18. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9.
19. Brynskov J, Foegh P, Pedersen G, Ellervik C, Kirkegaard T, Bingham A, et al. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 2002;51:37-43.
20. Reimund JM, Wittersheim C, Dumont S, Muller CD, Baumann R, Poindron P, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996;16:144-50.
21. Borruel N, Carol M, Casellas F, Antolín M, De Lara F, Espín E, et al. Increased mucosal tumour necrosis factor α production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 2002;51:659-64.
22. Casellas F, Papo M, Guarner F, Antolin M, Armengol JR, Malagelada JR. Intraluminal colonic release of immunoreactive tumour necrosis factor in chronic ulcerative colitis. Clin Sci 1994;87:453-8.
23. Braegger CO, Nichols S, Murch SH, Stephens S, McDonald TT. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
24. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of release tumor necrosis factor-alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-7.
25. Videla S, García-Lafuente A, Antolín M, Vilaseca J, Guarner F, Crespo E, et al. Antitumor necrosis factor therapy in rat chronic granulomatous colitis: critical dose-timing effects on outcome. J Pharmacol Exp Ther 1998;287:854-9.
26. Neuner P, Klosner G, Schauer E, Pourmojib M, Macheiner W, Grunwald C, et al. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 1994;83:262-7.
27. Hartmann G, Bidlingmaier C, Siegmund B, Albrich S, Schulze J, Tschoep K, et al. Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNF-alpha release. Am J Physiol 1999;277: G847-G54.
28. Armstrong AM, Foulkes R, Jennings G, Cannon C, Kirk SJ, Gardiner KR. Tumour necrosis factor inhibitors reduce the acute-phase response in hapten-induced colitis. Br J Surg 2001;88:235-40.
29. Loher F, Schmall K, Freytag P, Landauer N, Hallwachs R, Bauer C, et al. The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice. J Pharmacol Exp Ther 2003;305:549-56.
30. Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 1997;40:470-4.
31. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699-703.
32. Moreira AL, Sampaio EP, Zmuidzinas A. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;177:1675-80.
33. Gockel HR, Lugering A, Heidemenn J, Schmidt M, Domschke W, Kucharzik T, et al. Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway. J Immunol 2004;172:5103-9.
34. Facchini S, Candusso M, Martelossi S, Liubich M, Panfili E, Ventura A. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. J Pediatr Gastroenterol Nutr 2001;32:178-81.
35. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999;117:1271-7.
36. Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999;117:1278-87.
37. Dekkers PE, Lauw FN, Ten Hove T, Te Velde AA, Lumley P, Becherer D, et al. The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-α (TNFα) and TNF-α receptors during human endotoxemia. Blood 1999;94:2252-8.
38. Zhang Y, Xu J, Levin J, Hegen M, Li G, Robertshaw H, et al. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N- hydroxy-2,2-dimethyl-(3S) thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-α converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J Pharmacol Exp Ther 2004;309:348-55.
39. Beck G, Bottomley G, Bradshaw D, Brewster M, Broadhurst M, Devos R, et al. (E)-2(R)-[1(S)-(hydroxycarbamoyl)-4-phenyl-3-butenyl]-2′-isobutyl- 2′-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor α convertase. J Pharmacol Exp Ther 2002;302:390-6.
40. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti TNF-alpha monoclonal antibody Ca2 binds recombinant trasmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7: 251-9.
41. Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe S, Probert L. The mouse/human chimeric monoclonal antibody cA2 neutralizes in vitro and protects transgenic mice from cachexia and TNF-lethality in vivo. Cytokine 1995;7:15-25.
42. Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997;159:6276-82.
43. Ten Hove T, Van Montfrans C, Peppelenbosch MP, Van Deventer SJH. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-11.
44. Stephens S, Emtage S, Vetterlein O, Chaplin L, Bebbington C, Nesbitt A, et al. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 1995;85:668-74.
45. Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology (NY) 1994;12:899-903.
46. Den Broeder A, Van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002;29:2288-98.
47. Rose-John S, Schooltink H. CDP-870. Celltech/Pfizer. Curr Opin Investig Drugs 2003;4:588-92.
48. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151: 1548-61.
49. Terlizzese M, Simoni P, Antonetti F. In vitro comparison of inhibiting ability of soluble TNF receptor p75 (TBP II) vs. soluble TNF receptor p55 (TBP I) against TNF-alpha and TNF-beta. J Interferon Cytokine Res 1996;16:1047-53.
50. Lou J, Ythier A, Burger D, Lou J, Ythier A, Burger D, et al. Modulation of soluble and membrane-bound TNF-induced phenotypic and functional changes of human brain microvascular endothelial cells by recombinant TNF binding protein I. J Neuroimmunol 1997;77:107-15.
51. Trinchard-Lugan I, Ho-Nguyen Q, Bilham WM, Buraglio M, Ythier A, Munafo A. Safety, pharmacokinetics and pharmacodynamics of recombinant human tumour necrosis factor-binding protein-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers. Eur Cytokine Netw 2001;12:391-8.
52. Derx B, Taminiau J, Radema S. Tumor necrosis factor antibody treatment in Crohn's disease. Lancet 1993;342:173-4.
53. Van Dullemen HM, Van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn's disease with antitumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109: 129-35.
54. McCabe RP, Woody J, Van Deventer SJH. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with Crohn's disease. Gastroenterology 1996;110(Suppl 4):A962.
55. Targan SR, Hanauer SB, Van Deventer SJH, Mayer L, Present DH, Braaknan T. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997;337: 1029-35.
56. D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscpic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999;116:1029-34.
57. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997;349:521-4.
58. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, et al. CDP571 Crohn's Disease Study Group. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001;120: 1330-8.
59. Hanauer S, Present D, Targan SR. CDP571, a humanized monoclonal antibody to TNF-α, is well tolerated in Crohn's disease patients with previous hypersensitivity to infliximab. Gastroenterology 2003;124:A517.
60. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94.
61. D'Haens G, Swijsen C, Noman M, Lemmens L, Ceuppens J, Agbahiwe H, et al. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. Am J Gastroenterol 2001;96:2564-8.
62. Van den Brande JM, Braat H, Van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124;1774-85.
63. Rutgeerts P, Lemmens L, Van Assche G, Noman M, Borghini-Fuhrer I, Goedkoop R. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): Results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003;17: 185-92.
64. Mendoza JL, García-Paredes J, Cruz Santamaría DM, Lana R, Ramírez Fernández E, Rodríguez Asteaga E, et al. Tratamiento con infliximab y factores predictivos de respuesta en la enfermedad de Crohn. Rev Esp Enferm Dig 2002;94:269-79.
65. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
66. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359: 1541-9.
67. García Planella E, Doménech E, Esteve Comas M, Bernal I, Cabré E, Boix J, et al. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNF́ antibodies (infliximab). Eur J Gastroenterol Hepatol 2003;15: 351-4.
68. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13.
69. Feagan BG, Van S, Bala M, Bao W, Lichtenstein GR. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003;98:2232-8.
70. Lichtenstein GR, Van S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004;99:91-6.
71. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
72. Ochsenkülhn T, Göke B, Sackman M. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease. Am J Gastroenterol 2002;97:2022-5.
73. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:B76-85.
74. Chey WY, Hussain A, Ryan C, Potter GD, Shah A. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001;96:2373-81.
75. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7:83-8.
76. Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID, et al. Infliximab in moderately severe glucccorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52:998-1002.
77. Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002;97:2577-84.
78. Bermejo F, López-Sanromán A, Hinojosa J, Castro L, Jurado C, Gómez-Belda AB. Infliximab induce respuesta clínica, endoscópica e histológica en la colitis ulcerosa refractaria. Rev Esp Enferm Dig 2004;96:94-101.
79. Evans RC, Clarke L, Heath P, Stephens S, Morris AI, Rhodes JM. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther 1997;11:1031-5.
80. Papadakis KA, Treyzon L, Abreu MT, Fleshner PR, Targan SR, Vasiliauskas EA. Infliximab in the treatment of medically refractory indeterminate colitis. Aliment Pharmacol Ther 2003;18:741-7.
81. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease (Cochrane Review). En: The Cochrane Library, Issue 1. Oxford: Update Software, 2004.
82. Laine L, Hanauer SB. Considerations in the management of steroid-dependent Crohn's disease. Gastroenterology 2003;125:906-10.
83. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002;97:2962-72.
84. Martínez-Parra J, López-Larrea C, González S, Fuentes D, Diéguez A, Deschamps EM, et al. High serum tumor necrosis factor alfa levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002;97:2350-6.
85. Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, et al. Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002;97:2357-63.
86. Parsi A, Achkar JP, Richardson S, Katz J, Hammel JP, Lashner BA, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002;123:707-13.
87. Louis E, El Ghoul Z, Vermeire S, Dall'Ozzo S, Rutgeerts P, Paintaud G, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 2004;19:511-9.
88. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
89. Obrador A, López San Román A, Muñoz P, Fortún J, Gassull MA. Guía de consenso sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab. Gastroenterol Hepatol 2003;26:29-33.
90. Mow WS, Abreu-Martín MT, Papadakis KA, Pitchon HE, fargan SR, Vasiliauskas EA. High incidence of energy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004;2:309-13.
91. Baert F, Noman M, Vermeire S, Assche GV, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003:348:601-8.
92. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003;124:917-24.
93. Navarro F, Hanauer SB. Treatment of inflammatory bowel disease: safety and tolerability issues. Am J Gastroenterology 2003;98:S18-S23.
94. Colombel JF, Loftus EV, Tremaine WJ, Egan LI, Harmsen WS, Schleck CK, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
95. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004;27:307-24.